Peapod Bio teams up with Enamine to supercharge drug discovery
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
Angelini Ventures has already invested €125 million in 22 startups
Subscribe To Our Newsletter & Stay Updated